The WuXi AppTec-backed hepatitis specialist replenished its coffers in a series A-plus round led by Hillhouse Capital fund GL Capital.

Huahui Health, a China-based hepatitis treatment developer backed by pharmaceutical firm WuXi AppTec, has  received $78m in series A-plus funding, DealStreetAsia reported on Tuesday.

GL Ventures, the venture capital arm of private equity firm Hillhouse Capital, led the round, investign toegther with venture capital firm Matrix Partners China and Hankang Capital, possibly a vehicle for investment holding company Zhongjianxin Group.

Founded in 2015, Huahui Health is developing treatments for hepatitis B and is also conducting research on cancers and viruses.…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn